Opportunities in Pain Research with the NIH HEAL Initiative

Similar documents
NIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH

Director s Report to the National Advisory Council on Drug Abuse

Chronic Pain in Women and its Relationship to Opioid Addiction


Chronic Disease/Caregiver Management - Open Grant Opportunities

Advancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships

Opportunities for Statistical Modeling and Computation at the National Institute of Mental Health (NIMH), NIH

Liver Forum Cirrhosis Working Group Arun J. Sanyal

Corporate Presentation Asia Investment Series March 2018

Government Bioscience Grant (GBG) Report April 2015

Identification & Diagnosis of Cryptogenic Stroke What is NINDS/role

TRANS-NIH PLAN FOR HIV RELATED RESEARCH

First US Plan to Address Alzheimer s Disease

Advancing Addiction Science to Address the Opioid Crisis

Patients Driving Progress

Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America

2/20/2019. Source: Source:

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

The summit and its purpose

Accelerating Translation at Dana-Farber Cancer Institute*

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts Table of Contents (TOC)

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts Table of Contents (TOC)

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Translating Duke Health. Accelerating discovery and its translation

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018

Strategic priority to fight AMR

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016

Future of Diabetes Research in Europe JDRF Perspective

Request for Applications Post-Traumatic Stress Disorder GWAS

2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure

Alertness and Sleep Health Management Research & Technology. Strategic Opportunity Overview

What EU research policy can do for conditions such as chronic pain?

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Re: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities

Letter from the CEO. Dear Friends of IAVI,

Corporate Presentation

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

NIH FY 2017 Budget Roll-Out Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health February 9, 2016

Accelerating Innovation in Statistical Design


Delivering Value Through Personalized Medicine: An Industry Perspective

THERAPEUTIC DEVELOPMENT FOR OPIOID USE DISORDER & OVERDOSE PREVENTION AND REVERSAL

Parkinson s Research Program

Implications for public health research. Professor Bernie Hannigan Director - Research, Translation & Innovation

Oncology Drug Development Using Molecular Pathology

OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES

NIDA Director s Report to the National Advisory Councils of NIDA, NIAAA, & NCI February 4, Nora D. Volkow, M.D., Director

Grand Challenge and other funding opportunities at Cancer Research UK. Jamie Meredith, 9 th Dec 15

NCCIH s New Approach to Funding Clinical Trials Informational Webinar. April 18, 2017

Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards

Presentation to AGM 9 November Deborah Rathjen CEO & Managing Director

PSMA-617 License Transaction. October 2, 2017

PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER

Tuberous Sclerosis Complex Research Program

Drug Abuse & Addiction Research: Progress, Priorities, & Challenges

Downloaded from:

Safety Pharmacology Post Meeting Survey 2014

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts Table of Contents (TOC)

BIOMARKER DRIVEN EARLY PHASE ONCOLOGY CLINICAL TRIALS; CHALLENGES IN THE REAL WORLD SID KATUGAMPOLA CENTRE FOR DRUG DEVELOPMENT CANCER RESEARCH UK

Re: NOT-DK ; Request for Information (RFI): Soliciting Input on the Draft Strategic Plan for NIH Nutrition Research

The Challenge of Treating Pain

Using Biomarkers to Increase the Efficiency of Early Stage Drug Development

BRANCHED-CHAIN AMINO ACIDS FOUND TO REGULATE THE DEVELOPMENT AND PROGRESSION OF CANCER

Surveillance of Recent HIV Infections: Using a Pointof-Care Recency Test to Rapidly Detect and Respond to Recent Infections

AN INNOVATIVE APPROCH TOWARDS IDENTIFICAION OF NOVEL THERAPEUTIC DRUG TARGETS TO IMPROVE THE MANAGEMENT OF HEART FAILURE

NCI Cancer Moonshot. Christine Siemon National Cancer Institute, NIH. November 30, 2017

NIH Alzheimer s Disease Centers Panel Recommendations

Diet, Nutrition, and Cancer Mechanisms The Role of Clinical Trials

ITCC-P4 International Workshop

Five Prime Therapeutics, Inc. Corporate Overview

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

Collaborative Approaches for Developing Kidney Safety Biomarkers

ArQule Jefferies Global Healthcare Conference June 2015

UH2/UH3 Target Validation Projects Pre-application Technical Assistance Webinar for: RFA-RM RFA-RM RFA-RM

Successful collaboration for research development between the NIH and patient organisations

Innovation from the Foundation Sonya Dumanis, PhD

From Patients to Therapies. How could the BADIPS challenge progress towards improved in vitro models and novel patient therapies?

DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH. National Institute on Drug Abuse (NIDA) Organization Chart...

CHANGING CULTURE, BUILDING A SYSTEM, SUPPORTING PATIENTS AND STAFF. Andrew Suchocki, MD, MPH Medical Director Clackamas Health Centers

National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders

Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease Pennsylvania Avenue NW, Washington, DC June 20, 2017

TECHNOLOGICAL OPPORTUNITIES AND

Autism: The Federal Effort. Thomas R. Insel, M.D. National Institute of Mental Health NIH/DHHS 12/16/05

Discovery of Potent, Highly Selective, Broad Spectrum Antivirals

SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017

Surgeon General s Report

Risk Behaviour and Prevention

Supporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings

E11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Pediatric Population Step4

Scientific Discoveries Allow Development of Targeted Therapeutics for Individuals with Autism Spectrum Disorders

PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE

STRATEGIC PLAN

More cancer patients are being treated with immunotherapy, but

February 23, Q4 and Year-End 2016 Financial Results

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

NAMI Responses to the House Energy & Committee 21 st Century Cures Proposal

PA Opioid Overdose Reduction Technical Assistance Center

New Horizons for Vaccine R&D&I in Europe

Transcription:

Opportunities in Pain Research with the NIH HEAL Initiative Clinton Wright, M.D. Director, Division of Clinical Research National Institute of Neurological Disorders and Stroke, NIH September 20, 2018 1

NIH HEAL: Pain Research Priorities Enhance Pain Management Understand the biological underpinnings of chronic pain Accelerate the discovery and pre-clinical development of non-addictive pain treatments Advance new non-addictive pain treatments through the clinical pipeline Inform best practices for effective pain management while minimizing risk of addiction www.nih.gov/heal-initiative Collins, Koroshetz, Volkow; JAMA, 2018

Overview of current HEAL Programs for Pain Discovery Preclinical Development Clinical Trials Acute to Chronic Pain Signatures Discover and Validate Novel Targets for Safe and Effective Pain Treatment Trans-NIH Human-based Screening Platforms Preclinical Screening Platform for Pain Brand new programs Optimization of Non-addictive Therapies to Treat Pain Translating Discoveries Into Effective Stimulation Devices For Pain Treatment Discovery and Validation of Biomarkers, Biomarker Signatures, and Endpoints for Pain Indications NINDS HEAL Job Opportunities: https://www.ninds.nih.gov/about- NINDS/Jobs-At-NINDS/HEAL-Initiative- Employment-Opportunities Data and Asset Sharing Partnership Early Phase Pain Investigation Clinical Network Pain Effectiveness Research Trials + Network

HEAL - Understand the Neurobiology of Chronic Pain Acute to Chronic Pain Signatures Objective biosignatures to identify susceptibility or resilience to chronic pain Phenotyping Genotyping Sensory tests Imaging -omics Outcomes Mechanisms Novel therapeutic targets Cohort stratification Prevention Clinical Coordination Center, RFA-RM-18-035 Multisite Clinical Centers, RFA-RM-18-034, RFA-RM-18-033 Omics Data Generation Centers, RFA-RM-18-032 Data Integration and Resource Center, RFA-RM-18-031

HEAL - Discover and Validate Novel Pain Therapies To promote the basic science discovery and validation of targets for the treatment of pain that can be used to develop treatments with minimal side effects and little to no abuse/addiction liability Previously identified targets Nat Rev Drug Discov. 2017 Aug;16(8):545-564. NOT-NS-18-073 Administrative Supplements NOT-NS-18-080 Notice of Intent to Publish (R01) Basic biology target discovery projects Encourage collaboration from other fields Designed to reveal novel targets for small molecules, natural products, biologics, devices Devices: discovery of new sites for stimulation or electrophysiological signatures Open to all pain systems in CNS or periphery Pain target validation Novel in vitro/ex vivo assays Animal model systems development Multidisciplinary tools Multisite validation; robustness; reproducibility Validation of pharmacodynamic and predictive biomarkers

HEAL - Human Cell-based Preclinical Screening Platforms Develop human cell/tissue models Peripheral and central nervous system Normal and disease states ipsc-derived neurons, 3D printed organoids, tissue chips Advance investigational drugs for new targets Human tissue constructs to identify new probes/drug leads Automated chemical synthesis Artificial Intelligence to identify new chemical structures IND-enabling studies https://ncats.nih.gov/heal

HEAL - Preclinical Screening Platform for Pain A one-stop preclinical testing platform to promote the testing and characterization of non-addictive modalities for the treatment of pain Incentivize academia & industry to accelerate discovery of non-addictive, effective therapies Develop or refine animal models of pain conditions available to research community Generate high quality data to support partnerships, translational programs Small molecules Biologics Devices Natural products Preclinical Screening Platform In vitro µ-opioid receptor screening Acute pain models Chronic pain/disease models In vivo addiction screening Successful compounds/devices move to clinical trials

HEAL Translating BRAIN/SPARC/HEAL Discoveries into Effective Stimulation Devices for Pain Treatment Brain Research through Advancing Innovative Neurotechnologies Stimulating Peripheral Activity to Relieve Conditions The overall goal of this initiative is to translate diagnostic and therapeutic devices into humans to address the opioid epidemic through the development of non-addictive therapies that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Ø Goals Ø Leverage ongoing mapping / target discovery activities in BRAIN, SPARC, and other HEAL Initiatives Ø Expand Public Private Partnership efforts in SPARC & BRAIN to engage medical device industry to explore repurposing devices for new indications

HEAL - Discovery and Validation of Biomarkers, Endpoints and Signatures for Pain Conditions Define patient populations and treatment response to accelerate therapy development Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain RFA-NS-18-041 R61/R33 Goal is to facilitate discovery of robust biomarkers, biomarker signatures and objective endpoints for pain conditions NINDS Funding Opportunity: Analytical and/or Clinical Validation of a Candidate Biomarker for Pain NOT-NS-18-074 (RFA coming soon) R61/R33 Goal is to support analytical and clinical validation of candidate biomarkers for use in discovery and development of non-opiate alternatives to treatment of pain conditions using retrospective and/or prospective methods NIH Workshop Discovery of Biomarkers to Develop Transformational Non-Addictive Therapeutics for Pain November 14-15; Washington, DC Registration now open!

HEAL - Data and Asset Sharing Partnership Enable companies to access data that will speed development efforts Data sharing Relevant clinical, preclinical, pharmacokinetic data Asset Repurposing Accrue, analyze pharmacological assets from academia, pharma, device companies Structured data repository Data storage Report generation and analysis Develop dossiers on submitted assets Data sharing of prior pain efforts Industry partners review data from successful and failed pain therapy programs to inform in-house strategies Asset prioritization / scientific review Prioritization and triaging to clinical trials network

HEAL Early Phase Pain Investigation Clinical Network Improve quality, consistency, efficiency of pain clinical trials Clinical Coordination Center, Data Coordination Center, 10 specialized clinical sites (hub and spoke design) Incentivize, accelerate Phase II trials Focus on well-defined pain conditions with high-unmet need Reduce time to start, enroll, run, and complete trials NOT-NS-18-069 Test compounds and devices from industry, academia NOT-NS-18-057 Incorporate biomarker studies NOT-NS-18-058 Accommodate other platform trial designs RFAs coming soon!

HEAL - Pain Effectiveness Research Network and Trials To evaluate the effectiveness of pharmacologic and nonpharmacologic therapies for a broad array of pain conditions through phase 3 clinical trials Elucidate best treatment for different pain conditions, or best means of personalizing treatment for persons with similar pain conditions Focus of FOA(s): Comparative effectiveness research (CER) Trials of different pain therapies Different pain treatment paradigms Inform patients and the medical community on how best to treat painful conditions while minimizing potential for addiction 12